NCT00148928View on ClinicalTrials.gov

Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 1, 2005

Primary Completion Date

November 7, 2006

Study Completion Date

November 7, 2006

Conditions
Neoplasms, Prostate
Interventions
BIOLOGICAL

P501-AS15 vaccine

Trial Locations (8)

1070

GSK Investigational Site, Brussels

1200

GSK Investigational Site, Brussels

2300

GSK Investigational Site, Turnhout

25030

GSK Investigational Site, Besançon

31403

GSK Investigational Site, Toulouse

75248

GSK Investigational Site, Paris

89011

GSK Investigational Site, Auxerre

94805

GSK Investigational Site, Villejuif

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY